{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T05:42:09Z","timestamp":1783489329173,"version":"3.55.0"},"reference-count":37,"publisher":"BMJ","issue":"3","license":[{"start":{"date-parts":[[2020,3,24]],"date-time":"2020-03-24T00:00:00Z","timestamp":1585008000000},"content-version":"unspecified","delay-in-days":23,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2020,3,5]]},"published-print":{"date-parts":[[2020,3]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>The administration of androgen deprivation therapy (ADT) to patients with metastatic prostate cancer might be associated with some adverse effects such as anaemia; however, few studies have been performed in East Asian populations. This study aimed to investigate the association between ADT and iron-deficiency anaemia (IDA) among patients with prostate cancer in a population-based nationwide cohort.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>Cohort study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Setting<\/jats:title>\n                    <jats:p>Taiwan.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Participants<\/jats:title>\n                    <jats:p>Data for the cohort study were retrieved from the Taiwan National Health Insurance Research Database. Propensity score matching was used to select 7262 patients with prostate cancer who received ADT as the study group and 3631 patients who did not receive ADT as the control group.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Primary and secondary outcome measures<\/jats:title>\n                    <jats:p>This study individually tracked patients over a 3-year study period and identified those who were subsequently diagnosed with IDA following the index date.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The incidence rates of IDA in the study and control groups were 1.66 (95% CI CI 1.45 to 1.86) and 1.01 per 100 person-years (95%\u2009CI 0.78 to 1.25), respectively. Furthermore, proportional Cox regression revealed an HR of 1.62 (95% CI 1.24 to 2.12) for IDA in the study group after adjusting for patients\u2019 age, monthly income, geographic location, residential urbanisation level and incidence of hyperlipidaemia, diabetes, hypertension, coronary heart disease, inflammatory bowel disease, other cancers and gastrointestinal bleeding.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Compared with its non-use among patients with prostate cancer, ADT use was associated with a higher risk of IDA.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2019-034202","type":"journal-article","created":{"date-parts":[[2020,3,25]],"date-time":"2020-03-25T16:25:10Z","timestamp":1585153510000},"page":"e034202","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":6,"title":["Androgen deprivation therapy and the risk of iron-deficiency anaemia among patients with prostate cancer: a population-based cohort study"],"prefix":"10.1136","volume":"10","author":[{"given":"Fang-Jen","family":"Wu","sequence":"first","affiliation":[{"name":"Department of Pharmacy, West Garden Hospital, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I-Hsun","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, Tri-Service General Hospital, Taipei, Taiwan"},{"name":"School of Pharmacy, National Defense Medical Center, Taipei, Taiwan"},{"name":"Department of Pharmacology, National Defense Medical Center, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wu-Chien","family":"Chien","sequence":"additional","affiliation":[{"name":"Graduate Institute of Life Sciences, National Defense Medical Center, Taipei, Taiwan"},{"name":"Department of Medical Research, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan"},{"name":"School of Public Health, National Defense Medical Center, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jui-Hu","family":"Shih","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, Tri-Service General Hospital, Taipei, Taiwan"},{"name":"School of Pharmacy, National Defense Medical Center, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Chun","family":"Lin","sequence":"additional","affiliation":[{"name":"Research Center of Biostatistics, Taipei Medical University, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chin-Min","family":"Chuang","sequence":"additional","affiliation":[{"name":"Emergency Department, China Medical University Hospital, Taichung City, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yih-Dih","family":"Cheng","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, China Medical University Hospital, Taichung City, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0692-7408","authenticated-orcid":false,"given":"Li-Ting","family":"Kao","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, Tri-Service General Hospital, Taipei, Taiwan"},{"name":"School of Pharmacy, National Defense Medical Center, Taipei, Taiwan"},{"name":"Graduate Institute of Life Sciences, National Defense Medical Center, Taipei, Taiwan"},{"name":"School of Public Health, National Defense Medical Center, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2020,3,25]]},"reference":[{"key":"2025121222111014000_10.3.e034202.1","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1001\/jamaoncol.2015.0735","article-title":"The global burden of cancer 2013","volume":"1","author":"Fitzmaurice","year":"2015","journal-title":"JAMA Oncol"},{"key":"2025121222111014000_10.3.e034202.2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61947-4"},{"key":"2025121222111014000_10.3.e034202.3","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21442"},{"key":"2025121222111014000_10.3.e034202.4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMsa0910784"},{"key":"2025121222111014000_10.3.e034202.5","doi-asserted-by":"crossref","first-page":"2939","DOI":"10.1002\/cncr.31400","article-title":"Three-Month posttreatment prostate-specific antigen level as a biomarker of treatment response in patients with intermediate-risk or high-risk prostate cancer treated with androgen deprivation therapy and radiotherapy","volume":"124","author":"Bryant","year":"2018","journal-title":"Cancer"},{"key":"2025121222111014000_10.3.e034202.6","doi-asserted-by":"publisher","DOI":"10.1038\/ncpuro1296"},{"key":"2025121222111014000_10.3.e034202.7","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1038\/pcan.2016.69","article-title":"Lifestyle guidelines for managing adverse effects on bone health and body composition in men treated with androgen deprivation therapy for prostate cancer: an update","volume":"20","author":"Owen","year":"2017","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"2025121222111014000_10.3.e034202.8","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2014.07.010"},{"key":"2025121222111014000_10.3.e034202.9","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21642"},{"key":"2025121222111014000_10.3.e034202.10","doi-asserted-by":"crossref","first-page":"301","DOI":"10.5694\/j.1326-5377.2011.tb02979.x","article-title":"Bone and metabolic health in patients with non-metastatic prostate cancer who are receiving androgen deprivation therapy","volume":"194","author":"Grossmann","year":"2011","journal-title":"Med J Aust"},{"key":"2025121222111014000_10.3.e034202.11","doi-asserted-by":"publisher","DOI":"10.1001\/jama.294.2.238"},{"key":"2025121222111014000_10.3.e034202.12","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.urology.2016.05.058","article-title":"Increased fall risk in patients receiving androgen deprivation therapy for prostate cancer","volume":"95","author":"Wu","year":"2016","journal-title":"Urology"},{"key":"2025121222111014000_10.3.e034202.13","doi-asserted-by":"publisher","DOI":"10.1177\/1756283X11398736"},{"key":"2025121222111014000_10.3.e034202.14","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(20010615)91:12<2214::AID-CNCR1251>3.0.CO;2-P"},{"key":"2025121222111014000_10.3.e034202.15","doi-asserted-by":"crossref","first-page":"vii167","DOI":"10.1093\/annonc\/mdq284","article-title":"Anemia in cancer","volume":"21 Suppl 7","author":"Dicato","year":"2010","journal-title":"Ann Oncol"},{"key":"2025121222111014000_10.3.e034202.16","doi-asserted-by":"crossref","first-page":"4491","DOI":"10.3390\/nu6104491","article-title":"The use of dietary supplements to alleviate androgen deprivation therapy side effects during prostate cancer treatment","volume":"6","author":"Dueregger","year":"2014","journal-title":"Nutrients"},{"key":"2025121222111014000_10.3.e034202.17","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)60865-0"},{"key":"2025121222111014000_10.3.e034202.18","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.166.13.1380"},{"key":"2025121222111014000_10.3.e034202.19","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2010-0864"},{"key":"2025121222111014000_10.3.e034202.20","doi-asserted-by":"publisher","DOI":"10.1002\/hep.26648"},{"key":"2025121222111014000_10.3.e034202.21","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1182\/blood.V45.5.665.665","article-title":"Effects of testosterone and erythropoietin on erythroid colony formation in human bone marrow cultures","volume":"45","author":"Moriyama","year":"1975","journal-title":"Blood"},{"key":"2025121222111014000_10.3.e034202.22","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1002\/cncr.10673","article-title":"Initial decline in hemoglobin during neoadjuvant hormonal therapy predicts for early prostate specific antigen failure following radiation and hormonal therapy for patients with intermediate and high-risk prostate cancer","volume":"95","author":"D'Amico","year":"2002","journal-title":"Cancer"},{"key":"2025121222111014000_10.3.e034202.23","first-page":"1815","article-title":"Predictors of hemoglobin decline in non-metastatic prostate cancer patients on androgen deprivation therapy: a matched cohort study","volume":"19","author":"Timilshina","year":"2011","journal-title":"Support Care Cancer"},{"key":"2025121222111014000_10.3.e034202.24","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1097\/EDE.0000000000000678","article-title":"Androgen deprivation therapy and the risk of anemia in men with prostate cancer","volume":"28","author":"Hicks","year":"2017","journal-title":"Epidemiology"},{"key":"2025121222111014000_10.3.e034202.25","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.semradonc.2016.08.002","article-title":"Prostate cancer genetics: variation by race, ethnicity, and geography","volume":"27","author":"Rebbeck","year":"2017","journal-title":"Semin Radiat Oncol"},{"key":"2025121222111014000_10.3.e034202.26","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1177\/1557988318798279","article-title":"Global trends and prostate cancer: a review of incidence, detection, and mortality as influenced by race, ethnicity, and geographic location","volume":"12","author":"Taitt","year":"2018","journal-title":"Am J Mens Health"},{"key":"2025121222111014000_10.3.e034202.27","doi-asserted-by":"publisher","DOI":"10.1017\/S1368980008002401"},{"key":"2025121222111014000_10.3.e034202.28","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1111\/ajco.12874","article-title":"Preliminary efficacy and tolerability of chemohormonal therapy in metastatic hormone-na\u00efve prostate cancer: the first real-life experience in Asia","volume":"14","author":"Poon","year":"2018","journal-title":"Asia Pac J Clin Oncol"},{"key":"2025121222111014000_10.3.e034202.29","first-page":"1","article-title":"Incorporating development stratification of Taiwan townships into sampling design of large scale health interview survey","volume":"4","author":"Liu","year":"2006","journal-title":"J Health Manag"},{"key":"2025121222111014000_10.3.e034202.30","doi-asserted-by":"publisher","DOI":"10.1046\/j.1464-410X.1997.00234.x"},{"key":"2025121222111014000_10.3.e034202.31","first-page":"2547","article-title":"How are hemoglobin levels affected by androgen deprivation in non-metastatic prostate cancer patients?","volume":"12","author":"Choo","year":"2005","journal-title":"Can J Urol"},{"key":"2025121222111014000_10.3.e034202.32","doi-asserted-by":"publisher","DOI":"10.3275\/6149"},{"key":"2025121222111014000_10.3.e034202.33","first-page":"3877","article-title":"Anemia is associated with poor outcomes of metastatic castration-resistant prostate cancer, a systematic review and meta-analysis","volume":"10","author":"Dai","year":"2018","journal-title":"Am J Transl Res"},{"key":"2025121222111014000_10.3.e034202.34","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0025839","article-title":"Isolation and characterization of renal erythropoietin-producing cells from genetically produced anemia mice","volume":"6","author":"Pan","year":"2011","journal-title":"PLoS One"},{"key":"2025121222111014000_10.3.e034202.35","doi-asserted-by":"publisher","DOI":"10.1038\/206270a0"},{"key":"2025121222111014000_10.3.e034202.36","doi-asserted-by":"publisher","DOI":"10.1093\/gerona\/glt127"},{"key":"2025121222111014000_10.3.e034202.37","doi-asserted-by":"publisher","DOI":"10.1111\/acel.12052"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2019-034202","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T06:11:18Z","timestamp":1765606278000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2019-034202"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3]]},"references-count":37,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2020,3,25]]},"published-print":{"date-parts":[[2020,3]]}},"alternative-id":["10.1136\/bmjopen-2019-034202"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2019-034202","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3]]}}}